A meta-analysis based on propensity analysis studies comparing neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
NICT demonstrated superior survival benefits compared to NCRT in the treatment of ESCC, despite its lower pCR and MPR rate. The safety of the two treatment methods were comparable.
Authors
- Zixian Jin (ORCID: https://orcid.org/0000-0001-7303-5595)
- Bo Zhang (ORCID: https://orcid.org/0000-0002-0804-6404)
- Jian Zhang (ORCID: https://orcid.org/0000-0002-8411-8131)
- Jianfei Shen (ORCID: https://orcid.org/0000-0001-6123-0959)
- Jiani Zhu (ORCID: https://orcid.org/0000-0002-3533-556X)
Institutions
- Wenzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Zhejiang Taizhou Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s12672-025-03607-8
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00